Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12 Items
Title  Creator  Group name  Publishing year 
A metabolic crosstalk between liposarcoma and muscle sustains tumor growth Manteaux et al. EquipeLL 2024-09-12
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects Leenhardt et al. EquipeCTCS 2022-04-11
Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer Viala et al. EquipeCTCS 2021-07-15
A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy Chartron et al. EquipeCTCS 2021-12-10
Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma Cissé et al. EquipeLLC 2020-06-10
Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction Leenhardt et al. EquipeCTCS 2020-09-05
The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases Darlix et al. EquipeCTCS Jan 30, 2019
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help? Alexandre et al. EquipePC 2019
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology Griguolo et al. EquipeCTCS Nov 2018
Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Darlix et al. EquipeCTCS 11 15, 2016
Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients Darlix et al. EquipeCTCS 07 07, 2016
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases Jacot et al. EquipeELC 06 2016
12 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés